| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-05-18 | Dec-31-17 | Dec-05-17 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K/A | 10-K | 10-K/A |
| Revenues: |
| Clinical Services | 418.8 | 404.2 | 382.3 | 361.2 | 241.9 | 120.4 | 213.1 | 213.1 |
| Pharma Services | 91.0 | 80.2 | 62.1 | 47.7 | 34.9 | 13.3 | 27.2 | 27.2 |
| Other | | | | | | 143.0 | | |
| Total revenues | 509.7 | 484.3 | 444.4 | 408.8 | 276.7 | 276.7 | 240.3 | 239.2 |
| Revenue growth [+] | 5.2% | 9.0% | 8.7% | 47.7% | 15.2% | 15.7% | 3.6% | 3.2% |
| Clinical Services | 3.6% | 5.7% | 5.9% | 49.3% | 13.5% | -43.5% | | 1.4% |
| Pharma Services | 13.5% | 29.1% | 30.3% | 36.7% | 28.4% | -51.1% | | 25.4% |
| Cost of goods sold | 321.8 | 297.3 | 258.6 | 212.0 | 149.5 | 149.5 | 138.3 | 138.3 |
| Gross profit | 187.9 | 187.1 | 185.9 | 196.8 | 127.3 | 127.3 | 102.0 | 100.9 |
| Gross margin | 36.9% | 38.6% | 41.8% | 48.1% | 46.0% | 46.0% | 42.4% | 42.2% |
| Selling, general and administrative [+] | 310.7 | 283.9 | 191.7 | 175.3 | 114.2 | 114.2 | 94.4 | 94.4 |
| Sales and marketing | 67.3 | 62.6 | 47.9 | 47.4 | 29.4 | 29.4 | 24.0 | 24.0 |
| General and administrative | 243.4 | 221.3 | 143.8 | 128.0 | 84.8 | 84.8 | 70.4 | 70.4 |
| Research and development | 30.3 | 21.9 | 8.2 | 8.5 | 3.0 | 3.0 | 3.6 | 3.6 |
| Other operating expenses | -3.8 | | | | | | | |
| EBITDA [+] | -79.9 | -65.4 | 21.7 | 43.3 | 31.8 | 31.8 | 26.6 | 25.5 |
| EBITDA growth | 22.1% | -401.0% | -49.8% | 36.2% | 19.7% | 24.6% | -7.9% | -11.6% |
| EBITDA margin | -15.7% | -13.5% | 4.9% | 10.6% | 11.5% | 11.5% | 11.1% | 10.7% |
| Depreciation | 35.4 | 30.2 | 25.9 | 20.3 | 15.8 | 15.8 | 15.6 | 15.6 |
| EBITA | -115.3 | -95.6 | -4.2 | 22.9 | 16.0 | 16.0 | 11.0 | 9.9 |
| EBITA margin | -22.6% | -19.7% | -0.9% | 5.6% | 5.8% | 5.8% | 4.6% | 4.1% |
| Amortization of intangibles | 34.1 | 23.2 | 9.8 | 9.9 | 5.9 | 5.9 | 7.0 | 7.0 |
| EBIT [+] | -149.3 | -118.8 | -14.0 | 13.0 | 10.0 | 10.0 | 4.0 | 2.9 |
| EBIT growth | 25.7% | 748.7% | -207.6% | 29.5% | 153.5% | 246.0% | -29.5% | -48.4% |
| EBIT margin | -29.3% | -24.5% | -3.1% | 3.2% | 3.6% | 3.6% | 1.6% | 1.2% |
| Non-recurring items [+] | 8.3 | | | | | | 1.1 | |
| Loss (gain) on sale of business | | | | | | | 1.1 | |
| Interest expense | 1.5 | 5.1 | 7.0 | 3.7 | 6.2 | | 5.5 | |
| Interest expense | 1.5 | 5.1 | 7.0 | 3.7 | 6.2 | | 5.5 | |
| Other income (expense), net [+] | -0.2 | 108.8 | 7.0 | -5.6 | 0.0 | -6.2 | 0.0 | -5.6 |
| Gain (loss) on debt retirement | | | -1.4 | -1.0 | | | | |
| Other | -0.2 | -0.5 | 7.9 | -4.6 | 0.0 | 0.0 | 0.0 | 0.0 |
| Pre-tax income | -159.3 | -15.1 | -14.1 | 3.6 | 3.8 | 3.8 | -2.7 | -2.7 |
| Income taxes | -15.1 | -6.7 | -18.2 | -4.4 | 1.2 | 0.0 | -2.3 | 0.0 |
| Tax rate | 9.5% | 44.6% | 129.7% | | 31.0% | 0.0% | 85.1% | 0.0% |
| Net income | -144.3 | -8.3 | 4.2 | 8.0 | 6.1 | 6.1 | -10.9 | -10.9 |
| Net margin | -28.3% | -1.7% | 0.9% | 2.0% | 2.2% | 2.2% | -4.6% | -4.6% |
| |
| Basic EPS [+] | ($1.16) | ($0.07) | $0.04 | $0.08 | $0.07 | $0.07 | ($0.14) | ($0.14) |
| Growth | 1569.0% | -281.1% | -51.8% | 12.1% | -151.6% | -151.6% | -65.3% | -65.3% |
| Diluted EPS [+] | ($1.16) | ($0.07) | $0.04 | $0.08 | $0.07 | $0.07 | ($0.14) | ($0.14) |
| Growth | 1569.0% | -286.4% | -51.7% | 16.2% | -148.3% | -148.3% | -65.3% | -65.3% |
| |
| Shares outstanding (basic) [+] | 124.2 | 120.0 | 108.6 | 100.5 | 85.6 | 85.6 | 79.4 | 79.4 |
| Growth | 3.5% | 10.5% | 8.1% | 17.3% | 7.8% | 7.8% | 2.4% | 2.4% |
| Shares outstanding (diluted) [+] | 124.2 | 120.0 | 111.8 | 103.6 | 91.6 | 91.6 | 79.4 | 79.4 |
| Growth | 3.5% | 7.3% | 7.9% | 13.2% | 15.3% | 15.3% | 2.4% | 2.4% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |